ArticleCancer medicine2025
Analysis of Tryptophan Metabolic Profile Characteristics and Clinical Value in Differentiated Thyroid Cancer Patients.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The role of gut microbiota in thyroid cancer: from pathogenesis to diagnosis and treatment.Journal of endocrinological investigation · 2026Review
- Network toxicology and Mendelian randomization reveal pathogenic factors of monoethyl phthalate-induced thyroid cancer.European thyroid journal · 2026Article
- Profiling of the mycobiome and metabolome: a comparative study of benign pulmonary nodules and lung adenocarcinoma.Frontiers in cellular and infection microbiology · 2026Article
- Tryptophan metabolic reprogramming modulates cytokine networks in nucleos(t)ide analogue-treated chronic hepatitis B patients.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferentiated thyroid cancer (DTC) is the primary subtype of thyroid cancer. Timely diagnosis and intervention are crucial for improving prognosis and survival. However, the effectiveness of existing serum markers is limited, necessitating the discovery of new biomarkers.
methodsThis study utilized liquid chromatography-tandem mass spectrometry to analyze tryptophan metabolic profiles in serum samples from 105 DTC patients and 50 healthy controls. Independent predictors of DTC were identified through univariate intergroup comparisons and multivariate logistic regression analysis, leading to the development and validation of a new diagnostic model.
resultsSignificant differences were observed in 11 tryptophan metabolites between DTC patients and controls. Logistic regression identified nicotinamide, 3-hydroxyanthranilic acid, 5-hydroxytryptophan, melatonin, and indole-3-propionic acid as independent predictors. The nomogram prediction model was established based on these five metabolites, and according to the Hosmer-Lemeshow test, the model showed good fit. The five-metabolite diagnostic model demonstrated 84.8% sensitivity, 90.0% specificity, and an area under the ROC curve of 0.932. Decision curve analysis indicated that the model had significant advantages over serum thyroglobulin. DISCUSSION: Tryptophan metabolism exhibits distinct changes in DTC patients, with specific metabolites serving as early diagnostic markers. The five-metabolite panel demonstrates potential for improving early detection and management of DTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.